Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Change in Receivables: 2019-2024

Historic Change in Receivables for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to -$8.7 million.

  • C4 Therapeutics' Change in Receivables fell 52.68% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.8 million, marking a year-over-year decrease of 138.60%. This contributed to the annual value of -$8.7 million for FY2024, which is 184.22% down from last year.
  • Per C4 Therapeutics' latest filing, its Change in Receivables stood at -$8.7 million for FY2024, which was down 184.22% from $10.3 million recorded in FY2023.
  • Over the past 5 years, C4 Therapeutics' Change in Receivables peaked at $10.3 million during FY2023, and registered a low of -$8.7 million during FY2024.
  • Moreover, its 3-year median value for Change in Receivables was -$4.2 million (2022), whereas its average is -$871,333.
  • In the last 5 years, C4 Therapeutics' Change in Receivables skyrocketed by 986.33% in 2021 and then slumped by 444.48% in 2022.
  • Over the past 5 years, C4 Therapeutics' Change in Receivables (Yearly) stood at -$139,000 in 2020, then surged by 986.33% to $1.2 million in 2021, then crashed by 444.48% to -$4.2 million in 2022, then skyrocketed by 343.33% to $10.3 million in 2023, then plummeted by 184.22% to -$8.7 million in 2024.